New Edge Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History

New Edge Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$11.78 - $17.29 $37,648 - $55,258	-3,196 Reduced 97.86%	70 $1,000
Q3 2023 Nov 14, 2023	BUY	$11.69 - $15.02 $2,641 - $3,394	226 Added 7.43%	3,266 $38,000
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $214,199 - $336,758	-18,626 Reduced 85.97%	3,040 $40,000
Q1 2023 May 12, 2023	SELL	$14.34 - $21.05 $120,341 - $176,651	-8,392 Reduced 27.92%	21,666 $359,000
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $14,981 - $23,848	1,223 Added 4.24%	30,058 $559,000
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $203,575 - $447,519	28,835 New	28,835 $370,000
Q2 2022 Aug 09, 2022	SELL	$6.23 - $8.57 $119,547 - $164,449	-19,189 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $101,893 - $159,460	19,189 New	19,189 $159,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on New Edge Advisors, LLC with notifications on news.